Skip to main content

Table 2 Primary and secondary outcome measure responses at week 2 and week 4 of corticosteroid treatment

From: Inflammatory back pain in psoriatic arthritis is significantly more responsive to corticosteroids compared to back pain in ankylosing spondylitis: a prospective, open-labelled, controlled pilot study

Parameter

Axial psoriatic arthritis

Ankylosing spondylitis

Control

P value,

AxPsA vs. AS

Mean difference from baseline to week 2

 ASDAS

1.43 ± 0.39

1.03 ± 0.30

0.81 ± 0.26

0.004

 VAS

2.46 ± 0.91

1.66 ± 1.1

1.0 ± 0.94

0.003

 ASQoL

3.80 ± 1.82

2.4 ± 1.72

0.7 ± 0.67

<0.001

 BASFI

2.38 ± 0.68

0.95 ± 0.91

0.44 ± 0.41

<0.001

 BASDAI

1.93 ± 0.56

1.13 ± 0.33

0.84 ± 0.24

<0.001

Mean difference from baseline to week 4

 ASDAS

1.09 ± 0.32

0.77 ± 0.27

0.73 ± 0.24

0.007

 VAS

2.00 ± 0.92

1.33 ± 0.72

1.30 ± 0.82

0.054

 ASQoL

3.53 ± 1.35

2.26 ± 1.53

0.70 ± 0.67

<0.001

 BASFI

1.76 ± 0.82

0.78 ± 0.63

0.48 ± 0.24

<0.001

 BASDAI

1.57 ± 0.49

0.85 ± 0.45

0.62 ± 0.23

<0.001

  1. Data are presented as (mean ± SD)
  2. AxPsA axial psoriatic arthritis, AS ankylosing spondylits, VAS visual analogue scale, ASQoL Ankylosing Spondylitis Quality of Life, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, ASDAS Ankylosing Spondylitis Disease Activity Score